Etidronate Disodium(e tid’ ro nate)
CO Etidronate (CAN), Didronel, Gen-Etidronate (CAN)
PREGNANCY CATEGORY C
Drug Classes
Bisphosphonate
Calcium regulator
Therapeutic Actions
Slows normal and abnormal bone resorption; inhibits formation, growth, and dissolution of hydroxyapatite crystals.
Indications
Treatment of Paget disease of bone
Treatment of heterotopic ossification
Unlabeled uses: Prevention and treatment of corticosteroid-induced osteoporosis, prevention of osteoporosis with spinal cord injury
Contraindications and Cautions
Contraindicated with allergy to bisphosphonates, hypocalcemia, pregnancy, lactation, severe renal impairment, clinically overt osteomalacia.
Use cautiously with renal impairment, upper GI disease, enterocolitis.
Available Forms
Tablets—200, 400 mg
Dosages
Adults
Paget disease: 5–10 mg/kg/day PO for up to 6 mo; or 11–20 mg/kg/day PO for up to 3 mo. Doses above 10 mg/kg/day should be reserved for when lower doses are ineffective or when there is an urgent need to suppress rapid bone turnover or reduce elevated cardiac output. If retreatment is needed, wait at least 90 days between treatment regimens.
Heterotopic ossification: 20 mg/kg/day PO for 2 wk followed by 10 mg/kg/day PO for 10 wk (following spinal cord injury); 20 mg/kg/day PO for 1 mo preoperatively if due to total hip replacement, then 20 mg/kg/day PO for 3 mo postoperatively.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
